About the TILVANCE-301 trial
The TILVANCE-301 trial is currently enrolling patients with melanoma that is untreated, unresectable (cannot be removed by surgery), or metastatic (has spread to a different part of the body).
TILVANCE-301 will assess the safety of lifileucel in combination with pembrolizumab and its potential to:
- Reduce tumor size
- Slow tumor growth
- Eliminate tumors that show up on scans
- Extend patients’ lives without their cancer worsening
Patients may be eligible to participate in this trial if they:
- Are 18 to 70 years of age*
- Have unresectable or metastatic melanoma
- Have not received treatment for metastatic melanoma
- Have at least 1 tumor that can be removed by surgery and 1 tumor that can be tracked on scans
*Or older, with permission from the trial sponsor.
Here is what patients can expect in the trial
Patients who qualify will be randomly assigned to Group A or Group B (placed by chance).
Group A
Lifileucel + pembrolizumab
Obtain tumor tissue
Pembrolizumab treatment
Lifileucel treatment
Continue pembrolizumab treatment
Group B
Pembrolizumab
Pembrolizumab treatment
Patients in Group B whose cancer progresses may have the option to receive lifileucel
Find a trial location
The trial is currently recruiting patients at the following locations:
The list of trial locations will be updated as more sites become available. Check back if you do not yet see a convenient trial location. You can also contact a trial site to ask about travel support that may be offered.
Get started
This website is intended for a U.S. audience. TIL cell therapy is not yet approved by any regulatory or health agency for the investigational uses described in this website. This website is for educational purposes only and is not intended to replace discussions with a healthcare professional.
